Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. - Wikidata - wikimedia - TriplyDB

Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.

Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.

http://www.wikidata.org/entity/Q33919900

about

Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.

http://www.wikidata.org/entity/Q33919900

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Immunologic Effects of Maravir ...... ub-Study of the CADIRIS Trial.

@ast

Immunologic Effects of Maravir ...... ub-Study of the CADIRIS Trial.

@en

type

label

Immunologic Effects of Maravir ...... ub-Study of the CADIRIS Trial.

@ast

Immunologic Effects of Maravir ...... ub-Study of the CADIRIS Trial.

@en

prefLabel

Immunologic Effects of Maravir ...... ub-Study of the CADIRIS Trial.

@ast

Immunologic Effects of Maravir ...... ub-Study of the CADIRIS Trial.

@en

P1433

Q33919900-2EDC1DE1-A234-4948-97D5-31733E289FF5

P1476

Q33919900-CE3FD9BF-E536-4AEE-8DD8-8412184958BD

P2093

Q33919900-0F33D9EE-3352-447A-A9E7-6C42002BDB17

Q33919900-118EF22F-736D-4E03-80F5-6D0FD81B1C76

Q33919900-1817A79D-4F43-49A8-AA51-084E525461F4

Q33919900-31254B80-F43F-4391-96CA-66A7CCFC3DB7

Q33919900-352FF059-55D4-46FE-BCE7-4BFB723A55AA

Q33919900-6137E6C0-A57F-4654-84F7-64AD4CC005E5

Q33919900-65EB86EF-2FF0-43DD-924A-2F27A05E63B5

Q33919900-74FFBEB4-DEA9-407A-AFED-3687131F28EF

Q33919900-C21C5102-BFCC-496F-BDD9-60AB452FAFDE

Q33919900-DF6DDE9F-45A2-46F2-BAC1-FBF07EE2502A

P2860

Q33919900-0294D505-B720-4A63-9461-3C0F182A3812

Q33919900-1C95C8CD-2F3E-4D2A-9D8D-C26F0623E4EE

Q33919900-20C0BAFE-E516-4C79-BFB0-0449556778F5

Q33919900-21046A0C-E83C-49F3-95F3-16FF73327659

Q33919900-212A3540-CEE9-42D0-B8FE-9B10D1B64C60

Q33919900-29D8B782-ABEE-4B6F-A203-313BBF2EB417

Q33919900-2DBB06C3-9B83-4251-B71B-4FC5BB8358C3

Q33919900-333B87C3-69ED-45C5-B828-40B7111680C3

Q33919900-3B05FBBB-F907-4FCE-86A5-0F59F81AD159

Q33919900-3B2D4938-CCEE-4549-8C4D-F088107C1C46

P304

Q33919900-718A41D0-C255-4542-84D0-45EB323B9172

P31

Q33919900-EF547CC9-DCB2-4302-ACFF-A7B1BF9C193C

P356

Q33919900-E983CE03-49EE-4BEE-BF13-44C93BB41A09

P433

Q33919900-FCE3E952-48B2-4E3C-93BD-F942684056FD

P478

Q33919900-4B3FE224-17D6-4FD2-ABF6-A116BFD90E39

P50

Q33919900-78C59C33-1CA6-483A-8A55-868F1CF18111

P577

Q33919900-173C3364-5717-4B9B-9464-6164AD8533A8

P698

Q33919900-BC96B516-AFEE-4499-BB0C-9094350E7BFD

P932

Q33919900-3EF6270F-31FA-4D1E-94B1-35D57FB4AB74

P356

P1433

Pathogens & immunity

P1476

Immunologic Effects of Maravir ...... ub-Study of the CADIRIS Trial.

@en

P2093

Benigno Rodriguez

http://www.w3.org/2001/XMLSchema#string

Brian Clagget

http://www.w3.org/2001/XMLSchema#string

David H Canaday

http://www.w3.org/2001/XMLSchema#string

Ian Sanne

http://www.w3.org/2001/XMLSchema#string

Irini Sereti

http://www.w3.org/2001/XMLSchema#string

Juan G Sierra-Madero

http://www.w3.org/2001/XMLSchema#string

Livio Azzoni

http://www.w3.org/2001/XMLSchema#string

Michael M Lederman

http://www.w3.org/2001/XMLSchema#string

Mohammed S Rassool

http://www.w3.org/2001/XMLSchema#string

Yanink N Caro-Vega

http://www.w3.org/2001/XMLSchema#string

P2860

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.

The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery

Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.

Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study.

HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.

Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening

HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.

P304

151-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.20411/PAI.V2I2.181

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Pablo F Belaunzarán-Zamudio

P577

2017-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28736763

http://www.w3.org/2001/XMLSchema#string

P932

5518704

http://www.w3.org/2001/XMLSchema#string